TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01421186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR03087 phase 1 dose escalation
Description: Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle.~In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR03087
Description: MOR03087 will be administered according to the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (\> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (\> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.
Study: NCT01933035

Intervention type: OTHER
Intervention: Immune Thrombocytopenics
Description: Full blood count with extended platelet parameters

Intervention type: OTHER
Intervention: Hypo-proliferative thrombocytopenics
Description: Full blood count with extended platelet parameters
Study: NCT01421186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.
Study: NCT01673412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological tests
Description: social and economical level intellectual quotient (Raven's Progressive Matrices Standard) Coopersmith self-esteem inventory BECK Depression inventory Minimal Mental Status
Study: NCT02338219

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postpartum female pelvic floor muscle affection
Description: transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postpartum female pelvic floor muscle affection
Description: transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postpartum female pelvic floor muscle affection
Description: transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postpartum sexual function in Egyptian women.
Description: answering of the validated female sexual function index (F.S.F.I) three months postpartum period for same cases submitted to ultrasound.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postpartum sexual function in Egyptian women.
Description: answering of the validated female sexual function index (F.S.F.I) three months postpartum period for same cases submitted to ultrasound.
Study: NCT01062542

Intervention type: PROCEDURE
Intervention: Blood Draw and Ultrasound
Description: Patients will have a Blood sample taken to check hormone levels. Patients will also have an ultrasound test done to examine the ovaries. The ultrasound test is done by inserting a cylindrical probe into the vagina. The test has to be done this way to measures the ovaries accurately.

Intervention type: PROCEDURE
Intervention: Blood Draw and Ultrasound
Description: Patients will have a Blood sample taken to check hormone levels. Patients will also have an ultrasound test done to examine the ovaries. The ultrasound test is done by inserting a cylindrical probe into the vagina. The test has to be done this way to measures the ovaries accurately.

Intervention type: PROCEDURE
Intervention: Blood Draw and Ultrasound
Description: Patients will have a Blood sample taken to check hormone levels. Patients will also have an ultrasound test done to examine the ovaries. The ultrasound test is done by inserting a cylindrical probe into the vagina. The test has to be done this way to measures the ovaries accurately.
Study: NCT03277469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Radiation therapy that is delivered by inserting radioactive sources directly into a tumor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Radiation therapy that is delivered by inserting radioactive sources directly into a tumor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Tracker
Description: The MR tracking device consists of a series of radiofrequency (RF) microcoils that are embedded into brachytherapy catheter stylet. The RF microcoils allows for accurate spatial localization of an individual brachytherapy catheter.
Study: NCT04801147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells Vaccine
Description: Right after the surgical resection of the tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Immunotherapy will follow radiochemotherapy and will comprise 4 vaccinations every second week (injections I, II, III, IV), 2 further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) 2 months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only. In correspondence to the third vaccine injection (week 13), mTMZ will start.~Vaccine doses will be injected in the forearm of the patient.
Study: NCT02070016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Study: NCT04523103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artificial Assisted Activation
Description: Artificial assisted activation represents an effective technique to rescue the fertilization failure.
Study: NCT01933035

Intervention type: OTHER
Intervention: Control Population
Description: Full blood count with extended platelet parameters
Study: NCT00944723

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc-fortified bread
Description: Bread made with zinc-fortified wheat flour
Study: NCT04523103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artificial Assisted Activation
Description: Artificial assisted activation represents an effective technique to rescue the fertilization failure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artificial Assisted Activation
Description: Artificial assisted activation represents an effective technique to rescue the fertilization failure.
Study: NCT01363245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Telephone counseling: 7 calls over 6 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fax-to-quit
Description: referral to state smoking cessation 'quitline' for counseling - 1 call over 2 weeks
Study: NCT00883467

Intervention type: PROCEDURE
Group type: OTHER
Intervention: preconditioning
Description: 3 times of five minutes ischemia, produced by cuff inflation to a suprasystolic pressure positioned on the thigh

Intervention type: PROCEDURE
Group type: OTHER
Intervention: preconditioning
Description: 3 times of five minutes ischemia, produced by cuff inflation to a suprasystolic pressure positioned on the thigh

Intervention type: PROCEDURE
Group type: OTHER
Intervention: no preconditioning
Description: no preconditioning

Intervention type: PROCEDURE
Group type: OTHER
Intervention: no preconditioning
Description: no preconditioning
Study: NCT00944723

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc-fortified bread
Description: Bread made with zinc-fortified wheat flour

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc supplement
Description: Liquid supplement with zinc

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-fortified bread
Description: Daily consumption of non-fortified bread

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-fortified bread
Description: Daily consumption of non-fortified bread

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Daily intake of placebo supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo supplement
Description: Daily intake of placebo supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo supplement
Description: Daily intake of placebo supplement
Study: NCT04358276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention
Description: Complete online course

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermatoscope
Description: Receive dermatoscope

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive study packet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive study packet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive study packet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention (Physician)
Description: Receive physician directed letter and educational package

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention (Physician)
Description: Receive physician directed letter and educational package

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive text messages
Study: NCT02465502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
Study: NCT02274870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome Bupivacaine
Description: Administered via local tissue infiltration around the knee joint

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Administered via CFNB
Study: NCT04121065

Intervention type: PROCEDURE
Intervention: Blood withdrawal
Description: Blood withdrawal of maximum 60 ml performed to each enrolled patient during the study for primary and secondary endpoints evaluation.
Study: NCT01455272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic GPBPCI
Description: A G-CSF-primed PBPCI was planned within day 60 post-transplantation before hematologic relapse was diagnosed
Study: NCT00845208

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Network Support
Description: 12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Network Support
Description: 12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Network Support
Description: 12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
Study: NCT02372812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 12 mg of dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02255513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD200
Study: NCT00823043

Intervention type: DRUG
Intervention: timolol hemihydrate
Description: timolol hemihydrate 0.5% solution
Study: NCT02255513

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01485536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: Starting Dose: 70 mg/m2 by vein on days 1, 8, 15, and 22 days of a 28 day cycle.
Study: NCT00823043

Intervention type: DRUG
Intervention: timolol maleate
Description: timolol maleate in sorbate
Study: NCT02269371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
Study: NCT03841955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICC with high pressure tolerance
Description: Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the experimental group and given the intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rontine central venous catheter
Description: Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the control group and given the intervention.
Study: NCT04532658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching program
Description: * Charting system for outcomes feedback~* Profiling of individual surgeon~* Modules of improvement
Study: NCT03264885

Intervention type: OTHER
Group type: OTHER
Intervention: Incentive Care
Description: ICS is a novel intervention that incorporates patient education, social support, and financial assistance to assist individuals.
Study: NCT03389139

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near infrared spectroscopy (spinal anesthesia)
Description: effect of spinal anesthesia on regional renal and cerebral oxygen saturation in newborns

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near infrared spectroscopy (general anesthesia)
Description: effect of general anesthesia on regional renal and cerebral oxygen saturation in newborns
Study: NCT01487876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV DNA vaccine
Description: HBV DNA vaccine means that each volunteer received 4 injections of 4 mg DNA vaccine scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo means the arm in which each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
Study: NCT04693676

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prizloncabtagene Autoleucel
Description: Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
Study: NCT03663764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin a1
Description: All patients received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: HRT using the IMRT technique was administered. For patients with limited pulmonary or pleural metastases (≤3 lesions), stereotactic body radiation therapy (SBRT) could be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiotherapy
Description: All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .
Study: NCT03021577

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orbital Atherectomy System (OAS)
Description: The Cardiovascular Systems, Inc. (CSI) Diamondback 360 Coronary Orbital Atherectomy System (OAS) is a catheter-based system designed for facilitating stent delivery in patients with coronary artery lesions. The OAS consists of the hand-held CSI DIAMONDBACK 360 Coronary Orbital Atherectomy Device (OAD), the CSI Saline Infusion Pump (OAS pump), the CSI ViperWire Advance Coronary Guide Wire (VIPERWIRE guide wire), and the CSI ViperSlide Lubricant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotablator Rotational Atherectomy System
Description: The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: In a subset of patients (n= 20) a baseline cardiac MRI will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: In a subset of patients (n= 20) a baseline cardiac MRI will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
Study: NCT04034394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromoxibustion
Description: Electromoxibustion is a electric device that mimic the burning or moxa. Subjects in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside. The treatment will be delivered 3 times per week for 4 weeks.
Study: NCT01893281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Testosterone Solution
Description: Administered topically to axillae.
Study: NCT04034394

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee health education
Description: Subjects in this group will attend 2 lessons (120 minutes each) of health education related to knee OA symptom management in a small group of 5-7 subject. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR.
Study: NCT04387981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-orvepitant
Description: Oral solution of \[14C\]-orvepitant
Study: NCT01310309

Intervention type: DEVICE
Intervention: Coronary artery placement of a drug-eluting stent
Description: Coronary artery placement of a drug-eluting stent (XIENCE V® EECSS)
Study: NCT03036488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: On Day 1 of Cycles 1-4 of the neoadjuvant phase of the study OR on Days 1, 8, 15 of Cycles 1-4 of the neoadjuvant phase of the study; IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: On Day 1 of Cycles 1-4 of the neoadjuvant phase of the study OR on Days 1, 8, 15 of Cycles 1-4 of the neoadjuvant phase of the study; IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: On Days 1, 8 and 15 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: On Days 1, 8 and 15 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
Study: NCT04570527

Intervention type: PROCEDURE
Intervention: PCI
Description: percutaneous coronary intervention

Intervention type: PROCEDURE
Intervention: PCI
Description: percutaneous coronary intervention
Study: NCT00200174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene followed by combination therapy
Description: Patients will be randomized to either Raloxifene at 60mg P.O. (each day) for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
Study: NCT03089398

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Coronary Revascularization (isolated LIMA-LAD)
Description: sternal-sparing, off-pump, isolated LIMA-LAD revascularization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Coronary Revascularization (PCI)
Description: percutaneous revascularization of at least one non-LAD target

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Multi-vessel PCI with metallic drug-eluting stents (DES) including the LAD and or LM. Only FDA approved commercially available metallic drug-eluting stents may be used in this protocol.
Study: NCT02177955

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 7.5 mg Midazolam
Description: 7.5 mg midazolam 45 minutes before surgery